questionId
int64 337
65.5k
| question
stringlengths 11
209
| doc_id
stringlengths 8
8
| page_ids
stringlengths 15
680
| answers
stringlengths 5
436
| answer_page_idx
int64 0
20
| data_split
stringclasses 1
value |
|---|---|---|---|---|---|---|
1,001 | what is 'RE' in the letter? | sqjf0226 | ['sqjf0226_p0', 'sqjf0226_p1'] | ['preservation of documents and electronic data relating to actos', 'Preservation of Documents and Electronic Data relating to Actos'] | 0 | train |
1,002 | Heading of the first paragraph? | lzjf0226 | ['lzjf0226_p2', 'lzjf0226_p3', 'lzjf0226_p4', 'lzjf0226_p5', 'lzjf0226_p6'] | ['SIXTH OBJECTION'] | 1 | train |
1,003 | Name of the judge? | lzjf0226 | ['lzjf0226_p2', 'lzjf0226_p3', 'lzjf0226_p4', 'lzjf0226_p5', 'lzjf0226_p6'] | ['Patrick Hanna'] | 1 | train |
1,005 | When was the hearing before Judge? | lzjf0226 | ['lzjf0226_p2', 'lzjf0226_p3', 'lzjf0226_p4', 'lzjf0226_p5', 'lzjf0226_p6'] | ['July 25, 2013'] | 1 | train |
1,037 | What is the date mentioned? | ttjf0226 | ['ttjf0226_p4'] | ['January 14, 1999'] | 0 | train |
1,040 | What is the name of the company mentioned in the letterhead? | kmjf0226 | ['kmjf0226_p0', 'kmjf0226_p1', 'kmjf0226_p2', 'kmjf0226_p3'] | ['DEPARTMENT OF HEALTH & HUMAN SERVICES'] | 0 | train |
1,041 | What is the company name ? | ttjf0226 | ['ttjf0226_p4'] | ['ELI LILLY AND COMPANY'] | 0 | train |
1,042 | What is the fullform of NDA? | kmjf0226 | ['kmjf0226_p0', 'kmjf0226_p1', 'kmjf0226_p2', 'kmjf0226_p3'] | ['New drug application.', 'new drug application'] | 0 | train |
1,043 | What is the date mentioned? | gnjf0226 | ['gnjf0226_p0'] | ['August 16, 1999'] | 0 | train |
1,044 | What is the name of the addressee? | kmjf0226 | ['kmjf0226_p0', 'kmjf0226_p1', 'kmjf0226_p2', 'kmjf0226_p3'] | ['Mary Jo Pritza, MPH, PharmD', 'Ms. Pritza'] | 0 | train |
1,045 | To whom is this letter addressed? | gnjf0226 | ['gnjf0226_p0'] | ['Alan D. Mackenzie', 'Alan'] | 0 | train |
1,046 | What is the full form of TPA? | gnjf0226 | ['gnjf0226_p0'] | ['Takeda Pharmaceuticals America Inc.', 'Takeda Pharmaceuticals America, Inc.', 'Takeda Pharmaceuticals America'] | 0 | train |
1,047 | What kind of a letter is this ? | kmjf0226 | ['kmjf0226_p0', 'kmjf0226_p1', 'kmjf0226_p2', 'kmjf0226_p3'] | ['DISCIPLINE REVIEW LETTER'] | 0 | train |
1,048 | Which two companies have agreed to amend the Co-Promotion Agreement? | gnjf0226 | ['gnjf0226_p0'] | ['Takeda Pharmaceuticals America, Inc. ("TPA") and Eli Lilly and Company ("Lilly")'] | 0 | train |
1,049 | What is the name of the company? | lljf0226 | ['lljf0226_p0'] | ['THE UPJOHN COMPANY'] | 0 | train |
1,051 | What is the date mentioned? | lljf0226 | ['lljf0226_p0'] | ['September 21, 1993'] | 0 | train |
1,052 | To whom is this letter addressed? | lljf0226 | ['lljf0226_p0'] | ['Doctor Matsuzawa', 'Matsuzawa', 'Tai Matsuzawa, Ph.D.', 'Tai Matsuzawa, Ph.D'] | 0 | train |
1,053 | As a consequence of the decision Upjohn must decline participation with which company? | lljf0226 | ['lljf0226_p0'] | ['Takeda'] | 0 | train |
1,055 | A 79-year-old female was enrolled in the study for how many days? | gyjf0226 | ['gyjf0226_p1', 'gyjf0226_p2'] | ['200 days'] | 0 | train |
1,056 | The patient had a history of bladder cancer since when? | gyjf0226 | ['gyjf0226_p1', 'gyjf0226_p2'] | ['1996', 'since 1996'] | 0 | train |
1,057 | Who is the general manager of International development Dept. of Takeda Chemical Industires, Ltd.? | mljf0226 | ['mljf0226_p1'] | ['K. Kitazawa, Ph. D.'] | 0 | train |
1,059 | The woman had a positive history of what? | gyjf0226 | ['gyjf0226_p1', 'gyjf0226_p2'] | ['tobacco use'] | 0 | train |
1,061 | what is the name of the industry ? | mljf0226 | ['mljf0226_p1'] | ['TAKEDA CHEMICAL INDUSTRIES , LTD .', 'TAKEDA CHEMICAL INDUSTRIES, LTD.'] | 0 | train |
1,063 | How many pages are there in total? | mljf0226 | ['mljf0226_p1'] | ['2', 'Page 2 of 2'] | 0 | train |
1,065 | what is the month and date mentioned in this letter, at the top ? | mljf0226 | ['mljf0226_p1'] | ['october 25', 'October 25'] | 0 | train |
1,068 | What is the date mentioned? | nljf0226 | ['nljf0226_p0', 'nljf0226_p1'] | ['January 21, 1999'] | 0 | train |
1,070 | to which department it belongs to ? | gyjf0226 | ['gyjf0226_p1', 'gyjf0226_p2'] | ['department of health and human services.', 'DEPARTMENT OF HEALTH AND HUMAN SERVICES'] | 1 | train |
1,073 | what is the date of submission? | gyjf0226 | ['gyjf0226_p1', 'gyjf0226_p2'] | ['11/18/2002'] | 1 | train |
1,074 | what is the telephone number (include area code)? | gyjf0226 | ['gyjf0226_p1', 'gyjf0226_p2'] | ['847-383-3739'] | 1 | train |
1,076 | What is the serial number mentioned in the form? | gyjf0226 | ['gyjf0226_p1', 'gyjf0226_p2'] | ['5 0 1'] | 1 | train |
1,077 | what is the expiration date ? | gyjf0226 | ['gyjf0226_p1', 'gyjf0226_p2'] | ['november 30, 2002', 'November 30, 2002'] | 1 | train |
1,078 | what is the name of the sponsor ? | gyjf0226 | ['gyjf0226_p1', 'gyjf0226_p2'] | ['Takeda Pharmaceuticals North america , Inc.', 'Takeda Pharmaceuticals North America, Inc.'] | 1 | train |
1,079 | what has to be investigated before starting pioglitazone therapy? | psjf0226 | ['psjf0226_p4', 'psjf0226_p5'] | ['any macroscopic haematuria'] | 0 | train |
1,080 | what has been experienced commonly in patients taking actos in combination with insulin? | psjf0226 | ['psjf0226_p4', 'psjf0226_p5'] | ['heart failure', 'Heart failure'] | 0 | train |
1,082 | Under which department , The Cleveland Clinic Foundation operates? | zfkf0226 | ['zfkf0226_p0', 'zfkf0226_p1'] | ['Department of Cardiovascular Medicine.', 'Department of Cardiovascular Medicine'] | 1 | train |
1,083 | What is written in big bold letters at the bottom? | nljf0226 | ['nljf0226_p0', 'nljf0226_p1'] | ['DALY 19'] | 0 | train |
1,084 | Which medicine is used to treat type 2 diabetes mellitus? | psjf0226 | ['psjf0226_p4', 'psjf0226_p5'] | ['Actos/Competact'] | 0 | train |
1,087 | How many cases of bladder cancer from 12506 patients were reported? | psjf0226 | ['psjf0226_p4', 'psjf0226_p5'] | ['19 cases'] | 0 | train |
1,088 | What is the PO Box number? | zfkf0226 | ['zfkf0226_p0', 'zfkf0226_p1'] | ['931535'] | 1 | train |
1,090 | what is the IND mumber (if previously assigned ) ? | tyjf0226 | ['tyjf0226_p0', 'tyjf0226_p1', 'tyjf0226_p2', 'tyjf0226_p3'] | ['33,729'] | 2 | train |
1,091 | What is the serial number mentioned in the form? | tyjf0226 | ['tyjf0226_p0', 'tyjf0226_p1', 'tyjf0226_p2', 'tyjf0226_p3'] | ['4 9 7'] | 2 | train |
1,092 | what is the date of submission ? | tyjf0226 | ['tyjf0226_p0', 'tyjf0226_p1', 'tyjf0226_p2', 'tyjf0226_p3'] | ['11/1/02'] | 2 | train |
1,093 | what is the Name(s) of drug (include all available names: Trade , Generic, Chemical, Code)? | tyjf0226 | ['tyjf0226_p0', 'tyjf0226_p1', 'tyjf0226_p2', 'tyjf0226_p3'] | ['ACTOS (Pioglitazone HCI)', 'ACTOS (pioglitazone HCI)'] | 2 | train |
1,096 | what is the form approved : OMB No | tyjf0226 | ['tyjf0226_p0', 'tyjf0226_p1', 'tyjf0226_p2', 'tyjf0226_p3'] | ['0910-0014', '0910-0014.'] | 2 | train |
1,097 | What is the word written in bold on the top of the document? | psjf0226 | ['psjf0226_p0'] | ['Takeda'] | 0 | train |
1,098 | What is the date mentioned? | psjf0226 | ['psjf0226_p0'] | ['19th January 2012'] | 0 | train |
1,099 | what is the name of pharmaceuticals ? | xyjf0226 | ['xyjf0226_p0', 'xyjf0226_p1', 'xyjf0226_p2'] | ['Takeda Pharmaceuticals North America, Inc.', 'TAkeda pharmaceuticals North America ,INc.'] | 0 | train |
1,101 | to whom this letter is written ? | xyjf0226 | ['xyjf0226_p0', 'xyjf0226_p1', 'xyjf0226_p2'] | ['Ms. Haskins', 'janet L. haskins', 'Janet L. Haskins'] | 0 | train |
1,102 | When did Regulatory affairs department receive this letter? | xyjf0226 | ['xyjf0226_p0', 'xyjf0226_p1', 'xyjf0226_p2'] | ['JUN 16 2003'] | 0 | train |
1,105 | To whom was this letter written? | psjf0226 | ['psjf0226_p0'] | ['Healthcare Professional'] | 0 | train |
1,107 | What is the fifth point? | frjf0226 | ['frjf0226_p0', 'frjf0226_p1', 'frjf0226_p2', 'frjf0226_p3', 'frjf0226_p4', 'frjf0226_p5'] | ['WAC AND AWP generally;', 'WAC and AWP generally;'] | 2 | train |
1,108 | Education grants regarding which products? | frjf0226 | ['frjf0226_p0', 'frjf0226_p1', 'frjf0226_p2', 'frjf0226_p3', 'frjf0226_p4', 'frjf0226_p5'] | ['TPNA', 'TPNA products'] | 2 | train |
1,110 | To whom a copy of cover letter has to be sent ? | xyjf0226 | ['xyjf0226_p0', 'xyjf0226_p1', 'xyjf0226_p2'] | ['Ms. Jens Weber'] | 0 | train |
1,111 | Which reimbursement for TPNA pharmaceutical products is generally given? | frjf0226 | ['frjf0226_p0', 'frjf0226_p1', 'frjf0226_p2', 'frjf0226_p3', 'frjf0226_p4', 'frjf0226_p5'] | ['Medicare and Medicaid'] | 2 | train |
1,113 | What is the designation of Alfonso T. Perez, M.D.? | zfkf0226 | ['zfkf0226_p4'] | ['Vice President, Clinical Research'] | 0 | train |
1,114 | By whom was this agreement Agreed and Accepted? | zfkf0226 | ['zfkf0226_p4'] | ['Richard A. Rudick', 'Richard A. Rudick, M.D.', 'Richard A. Rudick, M.D. Chairman, Division of Clinical Research'] | 0 | train |
1,115 | What is the full form of FAR? | zfkf0226 | ['zfkf0226_p4'] | ['Federal Acquisitions Regulation'] | 0 | train |
1,116 | What is the number written above TAK-INDNDA-01577086? | xyjf0226 | ['xyjf0226_p0', 'xyjf0226_p1', 'xyjf0226_p2'] | ['425'] | 1 | train |
1,117 | What is the contact number of Ms. Jena Weber, Regulatory Project Manager? | xyjf0226 | ['xyjf0226_p0', 'xyjf0226_p1', 'xyjf0226_p2'] | ['301-827-6422'] | 1 | train |
1,118 | What is the full form of ODE? | xyjf0226 | ['xyjf0226_p0', 'xyjf0226_p1', 'xyjf0226_p2'] | ['Office of Drug Evaluation'] | 1 | train |
1,119 | What is written above Page 2 on the top? | xyjf0226 | ['xyjf0226_p0', 'xyjf0226_p1', 'xyjf0226_p2'] | ['IND 33, 729'] | 1 | train |
1,120 | what is the unit mentioned in the letter ? | zsjf0226 | ['zsjf0226_p0', 'zsjf0226_p1'] | ['7200'] | 0 | train |
1,121 | what is the date mentioned | zsjf0226 | ['zsjf0226_p0', 'zsjf0226_p1'] | ['9/23/93'] | 0 | train |
1,122 | What is the date of the signature of the chairman of the Division of clinical research? | zfkf0226 | ['zfkf0226_p4'] | ['5/8/07'] | 0 | train |
1,123 | Name of the first person in the To list? | zsjf0226 | ['zsjf0226_p0', 'zsjf0226_p1'] | ['PJ Daniels', 'pj Daniels'] | 0 | train |
1,124 | When did Regulatory affairs department receive this letter? | kmjf0226 | ['kmjf0226_p0', 'kmjf0226_p1', 'kmjf0226_p2', 'kmjf0226_p3'] | ['FEB 19 2007', 'Feb 19 2007'] | 0 | train |
1,125 | from whose desk this letter is written ? | zsjf0226 | ['zsjf0226_p0', 'zsjf0226_p1'] | ['timothy J Gumbleton', 'Timothy J. Gumbleton'] | 0 | train |
1,126 | Whose letter's copy is attached? | zsjf0226 | ['zsjf0226_p0', 'zsjf0226_p1'] | ['Dr. Mitchell', 'DR. Mitchell'] | 0 | train |
1,128 | what is the date mentioned ? | hmjf0226 | ['hmjf0226_p0'] | ['February 6, 1996', 'february 6 , 1996'] | 0 | train |
1,129 | to whom this letter is written ? | hmjf0226 | ['hmjf0226_p0'] | ['Dr . k. Kitazawa', 'Dr. K. KItazawa'] | 0 | train |
1,130 | this letter is written by whom ? | hmjf0226 | ['hmjf0226_p0'] | ['Tsuyoshi Suzuki , M S .', 'T. Suzuki'] | 0 | train |
1,131 | Which laboratory is T. Suzuki associated with ? | hmjf0226 | ['hmjf0226_p0'] | ['Drug Safety Research Laboratories', 'drug safety research laboratories .'] | 0 | train |
1,132 | what is the date mentioned in the letter | pljf0226 | ['pljf0226_p0', 'pljf0226_p1', 'pljf0226_p2', 'pljf0226_p3', 'pljf0226_p4', 'pljf0226_p5'] | ['august 8 , 2002', 'August 8, 2002'] | 0 | train |
1,133 | What is the name of the industry given here? | pljf0226 | ['pljf0226_p0', 'pljf0226_p1', 'pljf0226_p2', 'pljf0226_p3', 'pljf0226_p4', 'pljf0226_p5'] | ['Takeda chemical industries, LTD .', 'TAKEDA CHEMICAL INDUSTRIES, LTD.'] | 0 | train |
1,134 | to whom this letter is written ? | pljf0226 | ['pljf0226_p0', 'pljf0226_p1', 'pljf0226_p2', 'pljf0226_p3', 'pljf0226_p4', 'pljf0226_p5'] | ['Dr. Thom', 'Dr. Claire Thom'] | 0 | train |
1,135 | what is the name mentioned in CC | pljf0226 | ['pljf0226_p0', 'pljf0226_p1', 'pljf0226_p2', 'pljf0226_p3', 'pljf0226_p4', 'pljf0226_p5'] | ['Mr . S . Hamanaka', 'Mr. S. Hamanaka'] | 0 | train |
1,136 | Who sent this letter? | pljf0226 | ['pljf0226_p0', 'pljf0226_p1', 'pljf0226_p2', 'pljf0226_p3', 'pljf0226_p4', 'pljf0226_p5'] | ['Katsuhisa Saito', 'katsuhisa saito'] | 0 | train |
1,137 | what is Ref: code mentioned ? | pljf0226 | ['pljf0226_p0', 'pljf0226_p1', 'pljf0226_p2', 'pljf0226_p3', 'pljf0226_p4', 'pljf0226_p5'] | ['TPNA-TS-020808'] | 0 | train |
1,140 | what is the fax number mentioned in the letter at the top? | pljf0226 | ['pljf0226_p0', 'pljf0226_p1', 'pljf0226_p2', 'pljf0226_p3', 'pljf0226_p4', 'pljf0226_p5'] | ['06 6204 2244'] | 5 | train |
1,141 | what is the date and time mentioned ? | sljf0226 | ['sljf0226_p0'] | ['10/27/93 09:36:07'] | 0 | train |
1,142 | what is mentioned in the subject ? | sljf0226 | ['sljf0226_p0'] | ['pioglitazone statement', 'Pioglitazone statement'] | 0 | train |
1,143 | To whom this email was send? | sljf0226 | ['sljf0226_p0'] | ['PETER J. DANIELS', 'PJ DANIEL--PW17PO PETER J. DANIELS'] | 0 | train |
1,144 | what is the date mentioned in the forwarding note ? | sljf0226 | ['sljf0226_p0'] | ['10/26/93', '10/26/93 15:44'] | 0 | train |
1,145 | what is the time mentioned in the forwarding note ? | sljf0226 | ['sljf0226_p0'] | ['15:44'] | 0 | train |
1,146 | To whom this email was forwaded? | sljf0226 | ['sljf0226_p0'] | ['PLRUPPEL--RCC1 RUPPEL, PATRICIA', 'RUPPEL, PATRICIA'] | 0 | train |
1,147 | what is the name of the company | zsjf0226 | ['zsjf0226_p0', 'zsjf0226_p1'] | ['THE UPJOHN COMPANY'] | 1 | train |
1,148 | what is the date and year mentioned ? | zsjf0226 | ['zsjf0226_p0', 'zsjf0226_p1'] | ['september 21 , 1993', 'September 21, 1993'] | 1 | train |
1,150 | Which company is mentioned in the letterhead? | zsjf0226 | ['zsjf0226_p0', 'zsjf0226_p1'] | ['THE UPJOHN COMPANY'] | 1 | train |
1,151 | in which country the upjohn company is located ? | zsjf0226 | ['zsjf0226_p0', 'zsjf0226_p1'] | ['U.S.A', 'USA'] | 1 | train |
1,152 | what is the fax mentioned ? | pljf0226 | ['pljf0226_p0', 'pljf0226_p1', 'pljf0226_p2', 'pljf0226_p3', 'pljf0226_p4', 'pljf0226_p5'] | ['06 6204 2244'] | 2 | train |
1,153 | what is year date and time mentioned? | pljf0226 | ['pljf0226_p0', 'pljf0226_p1', 'pljf0226_p2', 'pljf0226_p3', 'pljf0226_p4', 'pljf0226_p5'] | ['2002 08/08 21:49'] | 2 | train |
1,154 | what is the name of the division ? | pljf0226 | ['pljf0226_p0', 'pljf0226_p1', 'pljf0226_p2', 'pljf0226_p3', 'pljf0226_p4', 'pljf0226_p5'] | ['Takeda Develop division', 'TAKEDA DEVELOP DIVISION'] | 2 | train |
1,155 | to whom they can ask directly to disclose the details of "promotion study"? | pljf0226 | ['pljf0226_p0', 'pljf0226_p1', 'pljf0226_p2', 'pljf0226_p3', 'pljf0226_p4', 'pljf0226_p5'] | ['FDA'] | 2 | train |
1,157 | what is the date mentioned in the letter | syjf0226 | ['syjf0226_p0', 'syjf0226_p1', 'syjf0226_p2'] | ['8 January 2003', '8 january 2003'] | 0 | train |
1,158 | To whom this letter is addressed? | syjf0226 | ['syjf0226_p0', 'syjf0226_p1', 'syjf0226_p2'] | ['MPDRAP I Leader'] | 0 | train |
1,159 | what is mentioned in the CC? | syjf0226 | ['syjf0226_p0', 'syjf0226_p1', 'syjf0226_p2'] | ['CEOs and general managers of pharmaceutical units', 'CEOs and General Managers of Pharmaceutical Units'] | 0 | train |
1,160 | combination therapy in the us market accounts for how much % of total actos sales . | syjf0226 | ['syjf0226_p0', 'syjf0226_p1', 'syjf0226_p2'] | ['64%', '64'] | 0 | train |
1,177 | What is the due date to evaluate data from actos 507? | qtjf0226 | ['qtjf0226_p3', 'qtjf0226_p4', 'qtjf0226_p5', 'qtjf0226_p6', 'qtjf0226_p7'] | ['August 5'] | 0 | train |
1,178 | who is the lead responsibility for developing additional monitoring plan for actos 508 | qtjf0226 | ['qtjf0226_p3', 'qtjf0226_p4', 'qtjf0226_p5', 'qtjf0226_p6', 'qtjf0226_p7'] | ['Amy hagaman', 'Amy Hagaman'] | 0 | train |
1,179 | what is the due date for "draft justification for actos 508" ? | qtjf0226 | ['qtjf0226_p3', 'qtjf0226_p4', 'qtjf0226_p5', 'qtjf0226_p6', 'qtjf0226_p7'] | ['august 12', 'August 12'] | 0 | train |
Subsets and Splits